Enovis Corporation Releases Preliminary Information About Its Performance for the Third Quarter 2023
19 Octubre 2023 - 5:58AM
Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today
released the following preliminary information about its
performance for the third quarter ended September 29, 2023.
Revenues for the three months ended September 29, 2023 are
expected to be between $414 and $418 million, compared to
approximately $383 million for the three months ended September 30,
2022, representing an increase of approximately 8 to 9%.
Adjusted EBITDA for the three months ended September 29, 2023 is
expected to be between $64 and $66 million, compared to
approximately $57 million for the three months ended September 30,
2022, representing an increase of approximately 12 to 15%.
The foregoing preliminary financial estimates reflect
management’s current views and may change as a result of
management’s review of results and other factors, including a wide
variety of significant business, economic and competitive risks and
uncertainties. Such preliminary financial information is subject to
the finalization and closing of the accounting books and records of
the Company (which have yet to be performed) and should not be
viewed as a substitute for full quarterly financial statements
prepared in accordance with U.S. GAAP. In the course of preparing
and finalizing the financial statements for the three months ended
September 29, 2023, the preliminary estimates for the three months
ended September 29, 2023 will be subject to change and the Company
may identify items that will require it to make adjustments to the
Company’s preliminary estimates described above. Any such changes
could be material. For these or other reasons, the preliminary
financial estimates for the three months ended September 29, 2023
may not ultimately be indicative of the Company’s results for such
periods and actual results may differ materially from those
described above. No independent registered public accounting firm
has audited, reviewed or compiled, examined or performed any
procedures with respect to these preliminary results, nor have they
expressed any opinion or any other form of assurance on these
preliminary estimated results.
Adjusted EBITDA is not prepared in accordance with U.S. GAAP and
is included in this press release because it is used by the
Company’s management to assess its operating performance. The table
below provides a reconciliation of preliminary adjusted EBITDA to
the closest comparable U.S. GAAP financial measure, net income
(loss) from continuing operations, for the three months ended
September 29, 2023.
Adjusted EBITDA represents net income or loss from continuing
operations excluding taxes, depreciation and amortization,
stock-based compensation costs and restructuring and other charges,
European Union Medical Device Regulation and other costs, strategic
transaction costs, insurance settlement (gain) loss, and inventory
step up costs. Adjusted EBITDA should not be considered in
isolation from, or as a substitute for, net income (loss) from
continuing operations or other measures calculated in accordance
with U.S. GAAP.
About Enovis Corporation
Enovis Corporation (NYSE: ENOV) is an
innovation-driven medical technology growth company dedicated to
developing clinically differentiated solutions that generate
measurably better patient outcomes and transform workflows. Powered
by a culture of continuous improvement, global talent and
innovation, the Company’s extensive range of products, services and
integrated technologies fuels active lifestyles in orthopedics and
beyond. The Company’s shares of common stock are listed in the
United States on the New York Stock Exchange under the symbol
ENOV.
Forward-Looking StatementsSome of the
statements contained in this press release that are not historical
facts are forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). The Company intends such forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 21E of the Exchange
Act. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Statements other than statements of historical fact
are statements that could be deemed forward-looking statements,
including statements regarding: the ability to consummate and
realize benefits from the Lima Acquisition; the impacts of the
completed spin-off of ESAB Corporation (“ESAB”) into an independent
publicly traded company (the “Separation”); the expected financial
and operating performance of, and future opportunities for, the
Company following the Separation; the impact of the COVID-19 global
pandemic; projections of revenue, profit margins, expenses, tax
provisions and tax rates, earnings or losses from operations,
impact of foreign exchange rates, cash flows, synergies or other
financial items; plans, strategies and objectives of management for
future operations including statements relating to potential
acquisitions, compensation plans or purchase commitments;
developments, performance, industry or market rankings relating to
products or services; future economic conditions or performance,
including the impact of increasing inflationary pressures; the
outcome of outstanding claims or legal proceedings; potential gains
and recoveries of costs; assumptions underlying any of the
foregoing; and any other statements that address activities, events
or developments that the Company intends, expects, projects,
believes or anticipates will or may occur in the future.
Forward-looking statements may be characterized by terminology such
as “believe,” “anticipate,” “should,” “would,” “could,” “may,”
“likely,” “intend,” “plan,” “will,” “expect,” “estimate,”
“project,” “positioned,” “strategy,” “targets,” “aims,” “seeks,”
“sees,” and similar expressions. These statements are based on
assumptions and assessments made by the Company’s management as of
the date of this press release in light of their experience and
perception of historical trends, current conditions, expected
future developments and are subject to risks, uncertainties and
other factors, including but not limited to: the risk that the
Company may not be able consummate the Lima Acquisition on the
anticipated terms or at all and other risks, uncertainties and
other factors set forth in the Company’s reports filed with the
U.S. Securities and Exchange Commission (the “SEC”), including its
most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q under the caption “Risk Factors,” as well as
the other risks and uncertainties set forth in the Company’s
other filings with the SEC. In addition, these statements are based
on assumptions that are subject to change. Any such forward-looking
statements are not guarantees of future performance and actual
results, developments and business decisions may differ materially
from those envisaged by such forward-looking statements. This press
release speaks only as of the date hereof. Enovis disclaims any
duty to update the information herein, except as required by
law.
Investor Relations ContactKyle RoseVice President,
Investor RelationsEnovis
Corporation+1-917-734-7450investorrelations@enovis.com
Media ContactKatie SweetVice President, Corporate
CommunicationsEnovis CorporationKatie.sweet@enovis.com
Enovis (NYSE:ENOV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enovis (NYSE:ENOV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024